Health Condition 1: T148- Other injury of unspecified body region
Conditions
Interventions
None listed
Sponsors
Torrent Pharmaceuticals Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female patients 18 to 65 years 2. Newly diagnosed cases of Closed Injury 3. Patients who are treated with receiving oral trypsin:chymotrypsin (6:1) 100000 AU for at least 2 weeks in outpatient department (OPD) in routine clinical practice 4. Patients willing for follow-up at scheduled visit as per protocol at same center
Exclusion criteria
Exclusion criteria: 1 Hypersensitivity to Trypsin: Chymotrypsin 2 Patients treated with gabapentanoids (pregabalin, gabapentin) for neuropathic pain
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Mean changes in LIKERT scale score for Stiffness, Pain and Functionality from baseline to end of 1st and 2nd week of treatmentTimepoint: baseline to end of 1st and 2nd week of treatment | — |
Secondary
| Measure | Time frame |
|---|---|
| Change in LIKERT scale score for improvement in Functional index from baseline at the end of 1st and 2nd week of treatmentTimepoint: end of 1st and 2nd week of treatment;Change in LIKERT scale score for pain from baseline to end of 1st and 2nd week of treatmentTimepoint: end of 1st and 2nd week of treatment;Clinical Global Improvement (CGI ) of efficacy at 2nd week of therapyTimepoint: 2nd week of therapy;Composite of the change in Stiffness score at 2nd week of therapyTimepoint: 2nd week of therapy;Percentage of patients requiring 3 tablets/day of rescue medication (Acetaminophen 500 or 650mg) at the end of 1st and 2nd week of therapyTimepoint: 1st and 2nd week of therapy;Safety assessment for Common Adverse events (1%)Timepoint: 1st and 2nd week of therapy | — |
Countries
India
Contacts
Public ContactDr Krishnaprasad K
Torrent Pharmaceuticals Ltd
Outcome results
None listed